PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 12449153

A simple model for straggling evaluation.

J W Wilson·J Tweed·H Tai·R K Tripathi
View original source ↗Export metadata ↓

Abstract

Some straggling models had largely been abandoned in favor of Monte Carlo simulations of straggling which are accurate but time consuming, limiting their application in practice. The difficulty of simple analytic models is the failure to give accurate values past 85% of the particle range. A simple model is derived herein based on a second order approximation upon which rapid analysis tools are developed for improved understanding of material charged particle transmission properties.

Explore related subjects

Alpha ParticlesAluminumCosmic RadiationElectronsElementary Particle InteractionsHeavy IonsModels, StatisticalProtonsRadiation ProtectionJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J W Wilson, J Tweed, H Tai, R K Tripathi. 2002. A simple model for straggling evaluation.. https://doi.org/10.1016/s0168-583x(02)01028-5

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Past exposure to densely ionizing radiation leaves a unique permanent signature in the genome.

Speculation has long surrounded the question of whether past exposure to ionizing radiation leaves a unique permanent signature in the genome. Intrachromosomal rearrangements or deletions are produced much more efficiently by densely ionizing radiation than by chemical mutagens, x-rays, or endogenous aging processes. Until recently, such stable intrachromosomal aberrations have been very hard to detect, but a new chromosome band painting technique has made their detection practical. We report the detection and quantification of stable intrachromosomal aberrations in lymphocytes of healthy former nuclear-weapons workers who were exposed to plutonium many years ago. Even many years after occupational exposure, more than half the blood cells of the healthy plutonium workers contain large (>6 Mb) intrachromosomal rearrangements. The yield of these aberrations was highly correlated with plutonium dose to the bone marrow. The control groups contained very few such intrachromosomal aberrations. Quantification of this large-scale chromosomal damage in human populations exposed many years earlier will lead to new insights into the mechanisms and risks of cytogenetic damage.

Alpha Particles↗
PubMed2003

Preclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2.

The control of micrometastatic breast cancer remains problematic. To this end, we are developing a new adjuvant therapy based on (213)Bi-PAI2, in which an alpha-emitting nuclide ((213)Bi) is chelated to the plasminogen activator inhibitor-2 (PAI2). PAI2 targets the cell-surface receptor bound urokinase plasminogen activator (uPA), which is involved with the metastatic spread of cancer cells. We have successfully labelled and tested recombinant human PAI2 with the alpha radioisotope (213)Bi to produce (213)Bi-PAI2, which is highly cytotoxic towards breast cancer cell lines. In this study, the 2-day postinoculation model, using MDA-MB-231 breast cancer cells, was shown to be representative of micrometastatic disease. Our in vivo efficacy experiments show that a single local injection of (213)Bi-PAI2 can completely inhibit the growth of tumour at 2 days postcell inoculation, and a single systemic (i.p.) administration at 2 days causes tumour growth inhibition in a dose-dependent manner. The specific role of uPA as the target for (213)Bi-PAI2 therapy was determined by PAI2 pretreatment blocking studies. In vivo toxicity studies in nude mice indicate that up to 100 microCi of (213)Bi-PAI2 is well tolerated. Thus, (213)Bi-PAI2 is successful in targeting isolated breast cancer cells and preangiogenic cell clusters. These results indicate the promising potential of (213)Bi-PAI2 as a novel therapeutic agent for micrometastatic breast cancer.

Alpha Particles↗